<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359810</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS9924</org_study_id>
    <nct_id>NCT04359810</nct_id>
  </id_info>
  <brief_title>Plasma Therapy of COVID-19 in Critically Ill Patients</brief_title>
  <official_title>A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max R. O'Donnell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York Blood Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized blinded phase 2 trial will assess the efficacy and safety of Anti-SARS-CoV-2
      convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may
      participate. A total of 105 eligible subjects will be randomized in a 2:1 ratio to receive
      either high-titer anti-SARS-CoV-2 plasma or non-convalescent fresh frozen plasma (control
      plasma).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no approved therapies for Coronavirus disease 2019 (COVID-19), also known as severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Exposure to viruses results in an
      adaptive immune response that commonly include antibodies with neutralization activity.
      Plasma from subjects who have recovered from viral infections has been used to both prevent
      or treat disease. Notable examples of the successful use of convalescent plasma (CP) include
      influenza, measles, Argentine hemorrhagic fever, Middle East respiratory syndrome (MERS),
      Ebola and severe acute respiratory syndrome (SARS). In recent work in China, an open label
      safety trial of CP in patients with COVID-19 suggested a substantive benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 105 eligible subjects will be randomized in a 2:1 ratio to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or non-convalescent fresh frozen plasma (control plasma).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Improvement</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The efficacy of treatment will be determined by determining the time-to-clinical improvement, defined as the time from randomization to either an improvement of one point on a seven-category ordinal scale or alive discharge from the hospital, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of SARS-CoV-2 PCR Positivity</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SARS-CoV-2 PCR Positivity</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Need for Supplemental Oxygen</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Compare duration of need for supplemental oxygen and/or mechanical ventilation amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Compare duration of hospitalization amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital 28-day Mortality Rate</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Compare in-hospital and 28-day mortality amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma (anti-SARS-CoV-2 plasma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent plasma (1 unit; ~200-250 mL) collected from a volunteer who recovered from COVID-19 disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-convalescent Plasma (control plasma)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-convalescent plasma (1 unit; ~200-250 mL) of standard plasma collected prior to December 2019</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma (anti-SARS-CoV-2 plasma)</intervention_name>
    <description>Convalescent Plasma that contains antibody titers against SARS-CoV-2</description>
    <arm_group_label>Convalescent Plasma (anti-SARS-CoV-2 plasma)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-convalescent Plasma (control plasma)</intervention_name>
    <description>Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)</description>
    <arm_group_label>Non-convalescent Plasma (control plasma)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent prior to performing study
             procedures or have a legally authorized representative available to do so.

          -  Age ≥18 years

          -  Evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal swab sample within 7
             days of randomization

          -  Peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air or requiring
             supplemental oxygen, non-invasive or invasive mechanical ventilation at screening

          -  Evidence of infiltrates on chest radiography

          -  Females of childbearing age and males, must be willing to practice an effective
             contraceptive method or remain abstinent during the study period.

        Exclusion Criteria:

          -  Participation in another clinical trial of anti-viral agent(s) for COVID-19

          -  Receipt of any anti-viral agent(s) with possible activity against SARS-CoV-2 &lt;24 hours
             prior to study drug administration

          -  Mechanically ventilated (including veno-venous (VV)-ECMO) ≥ 5 days

          -  Severe multi-organ failure

          -  History of prior reactions to transfusion blood products meeting definitive case
             definition criteria, at least severe severity, and probable or definite imputability
             per National Healthcare Safety Network (NHSN)/Centers for Disease Control and
             Prevention (CDC) criteria

          -  Known Immunoglobulin A (IgA) deficiency

          -  Females who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max O'Donnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Max O'Donnell, MD</last_name>
    <phone>212-305-5794</phone>
    <email>mo2130@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Eisenberger, MD</last_name>
    <phone>212-305-0983</phone>
    <email>abe6@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center/NYP</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max O'Donnell, MD</last_name>
      <phone>212-305-5794</phone>
      <email>mo2130@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Walter I. Lipkin, MD</last_name>
      <phone>646-361-2525</phone>
      <email>wil2001@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016 Sep;22(9):1554-61. doi: 10.3201/eid2209.151164.</citation>
    <PMID>27532807</PMID>
  </reference>
  <reference>
    <citation>Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017 Nov 30;36(27):4391-4400. doi: 10.1002/sim.7501. Epub 2017 Sep 15.</citation>
    <PMID>28913837</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702. Review.</citation>
    <PMID>7985997</PMID>
  </reference>
  <reference>
    <citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6.</citation>
    <PMID>15616839</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Max R. O'Donnell</investigator_full_name>
    <investigator_title>Florence Irving Assistant Professor of Medicine and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

